Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

SARS-CoV-2 spike protein plasmid DNA vaccine CORVax

A vaccine consisting of DNA plasmids encoding the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) surface antigen spike (S) protein, with potential immunizing activity against SARS-CoV-2. Upon administration of the SARS-CoV-2 S protein plasmid DNA vaccine CORVax and following electroporation (EP), the DNA plasmids enter the cells and the cells produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:SARS-CoV-2 S-protein DNA vaccine CORVax
SARS-CoV-2 S-protein plasmid DNA vaccine CORVax
Code name:CORVax
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search